Open AccessDouble‐blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension
Author(s) -
S. Ram C. Venkata,
Ames Richard P.,
Applegate William B.,
Burris James F.,
Davidov Michael E.,
Mroczek William J.
Publication year - 1994
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960170506
Subject(s) - amlodipine , hydrochlorothiazide , medicine , blood pressure , urology , heart rate , endocrinology , pharmacology , cardiology
In the final analysis of this study at Week 26,26% of the patients randomized to receive amlodipine attained blood pressure control with amlodipine alone compared with 33% of the patients allocated to hydrochlorothiazide (HCTZ). Neither amlodipine nor HCTZ produced clinically significant changes in pulse rate or in the electrocardiogram. Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (Δ22.9 ± 8.6 mg/dl). The incidence of side effects and the rate of patient withdrawal in the amlodipine and HCTZ groups were comparable. As expected, HCTZ therapy caused well‐recognized biochemical alterations in cholesterol and potassium levels, whereas amlodipine was metabolically neutral.